Penn Medicine Provider

About me

  • Research Associate Professor of Radiology

Insurance accepted

My Locations

Qualifications and experience

Treatments and Conditions

My research

Gupta PK, Li LZ, Singh DK, Nova S, Arias-Mendoza F, Orlovskiy S, Chawla S, Nelson DS, Farwell MD, Nath K* MRS and Optical Imaging Studies of Therapeutic Response to Combination Therapy Targeting BRAF/MEK in Murine Melanomas , Acad Radiol : 2025 *Corresponding Author


Orlovskiy S, Gupta PK, Arias-Mendoza F, Singh DK, Nova S, Nelson DS, Narayan V, Koch CJ, Hardy M, You M, Kalyanaraman B, Nath K* Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A (1)H and (31)P Magnetic Resonance Spectroscopy Study , Int J Mol Sci., 26(2): 2025 *Corresponding Author


Gupta PK*, Orlovskiy S, Arias-Mendoza F, Nelson DS, Nath K* 1H and 31P Magnetic Resonance Spectroscopic Metabolomic Imaging: Assessing Mitogen-Activated Protein Kinase Inhibition in Melanoma , Cells, 13(14): 2024 *Corresponding Author,1220


Nath K*, Gupta PK, Basappa J, Wang S, Sen N, Lobello C, Tomar JS, Shestov AA, Orlovskiy S, Arias-Mendoza F, Rauert-Wunderlich H, Nelson DS, Glickson JD, Wasik MA* Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition , J Transl Med. , 22(1): 2024 *Corresponding Author,622


Orlovskiy S, Gupta PK, Roman J, Arias-Mendoza F, Nelson DS, Koch CJ, Narayan V, Putt ME and Nath K* Lonidamine Induced Selective Acidification and De-Energization of Prostate Cancer Xenografts: Enhanced Tumor Response to Radiation Therapy , Cancers, 16(1384): 2024 *Corresponding Author


Gupta PK, Orlovskiy S, Arias-Mendoza F, Nelson DS, Osborne A, Pickup S, Glickson JD, Nath K* Metabolic Imaging Biomarkers of Response to Signaling Inhibition Therapy in Melanoma , Cancers, 16: 2024 *Corresponding Author, 365


Gupta PK, Orlovskiy S, Roman J, Pickup S, Nelson DS, Glickson JD, Nath K* pH-dependent structural characteristics of lonidamine: (1)H and (13)C NMR study , RSC Adv, 13(29): 2023. *Corresponding Author,19813-19816


Nath K, Arias-Mendoza F, Xu HN, Gupta PK, Li LZ Feasibility of non-invasive measurement of tumor NAD(H) by in vivo phosphorus-31 magnetic resonance spectroscopy , Adv Exp Med Biol, 1395: 2022 ,237-242


Xu HN, Feng M, Nath K, Nelson DS, Roman J, Zhao H, Lin Z, Glickson JD, Li LZ Optical Redox Imaging of Lonidamine Treatment Response of Melanoma Cells and Xenografts , Molecular imaging and biology, 21(3): 2019,426-435


*Nath K, Roman J, Nelson DS, Guo L, Lee SC, Orlovskiy S, Muriuki K, Heitjan DF, Leeper DB, Blair IA, Putt ME, Glickson JD Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin , Scientific reports, 8(1): 2018 *Corresponding Author,14654